See more : Jerónimo Martins, SGPS, S.A. (JRONY) Income Statement Analysis – Financial Results
Complete financial analysis of Kyowa Kirin Co., Ltd. (KYKOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyowa Kirin Co., Ltd., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Brookdale Senior Living Inc. 7. (BKDT) Income Statement Analysis – Financial Results
- IVF Hartmann Holding AG (VBSN.SW) Income Statement Analysis – Financial Results
- Sunworks, Inc. (SUNWQ) Income Statement Analysis – Financial Results
- Gakken Holdings Co., Ltd. (9470.T) Income Statement Analysis – Financial Results
- Tailwind International Acquisit (TWNI-WT) Income Statement Analysis – Financial Results
Kyowa Kirin Co., Ltd. (KYKOF)
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 442.23B | 398.37B | 352.25B | 318.35B | 305.82B | 346.53B | 353.38B | 343.02B | 364.32B | 333.45B | 340.61B | 333.16B | 343.72B | 413.74B | 0.00 | 392.12B | 354.27B | 353.44B | 358.96B | 348.84B | 359.29B | 378.67B | 375.61B | 374.91B |
| Cost of Revenue | 111.21B | 86.92B | 87.85B | 80.44B | 79.62B | 119.34B | 129.06B | 134.53B | 138.92B | 127.54B | 127.85B | 122.47B | 146.17B | 222.76B | 0.00 | 247.20B | 222.85B | 226.46B | 226.85B | 219.33B | 232.96B | 249.92B | 251.67B | 248.04B |
| Gross Profit | 331.03B | 311.46B | 264.40B | 237.91B | 226.20B | 227.19B | 224.32B | 208.49B | 225.39B | 205.90B | 212.76B | 210.69B | 197.56B | 190.98B | 0.00 | 144.92B | 131.43B | 126.98B | 132.11B | 129.51B | 126.33B | 128.74B | 123.95B | 126.87B |
| Gross Profit Ratio | 74.85% | 78.18% | 75.06% | 74.73% | 73.97% | 65.56% | 63.48% | 60.78% | 61.87% | 61.75% | 62.46% | 63.24% | 57.48% | 46.16% | 0.00% | 36.96% | 37.10% | 35.93% | 36.80% | 37.13% | 35.16% | 34.00% | 33.00% | 33.84% |
| Research & Development | 81.51B | 62.90B | 57.68B | 52.31B | 53.51B | 48.59B | 49.16B | 53.79B | 51.52B | 47.67B | 43.63B | 44.78B | 47.93B | 44.06B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 133.23B | 166.19B | 145.61B | 126.61B | 117.32B | 119.81B | 112.96B | 0.00 | 0.00 | 169.00M | 205.00M | 145.00M | 132.00M | 0.00 | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Selling & Marketing | 29.85B | 47.33B | 38.56B | 30.28B | 24.03B | 19.48B | 13.71B | 15.86B | 16.71B | 15.96B | 16.42B | 15.19B | 15.27B | 15.66B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 163.08B | 166.19B | 145.61B | 126.61B | 117.32B | 119.81B | 112.96B | 15.86B | 16.71B | 15.96B | 16.42B | 15.19B | 15.40B | 15.66B | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Other Expenses | 0.00 | -21.36B | -5.63B | -9.19B | -14.58B | 15.50B | -1.76B | 753.00M | 255.00M | -141.00M | -392.00M | -1.00M | -124.00M | 1.13B | 0.00 | -2.05B | 0.00 | -1.47B | -4.05B | -11.44B | 0.00 | -5.61B | 6.09B | 2.06B |
| Operating Expenses | 244.59B | 229.08B | 203.29B | 178.92B | 170.83B | 168.40B | 162.11B | 176.85B | 181.62B | 169.73B | 160.98B | 157.78B | 112.90B | 106.73B | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Cost & Expenses | 355.79B | 316.00B | 291.14B | 259.36B | 250.45B | 287.74B | 291.17B | 311.38B | 320.55B | 297.27B | 288.83B | 280.25B | 259.06B | 329.49B | 0.00 | 352.73B | 323.58B | 327.91B | 325.46B | 322.00B | 343.20B | 358.31B | 357.90B | 353.25B |
| Interest Income | 4.87B | 3.32B | 1.11B | 1.80B | 1.03B | 839.00M | 806.00M | 476.00M | 459.00M | 629.00M | 775.00M | 604.00M | 497.00M | 362.00M | 0.00 | 1.80B | 528.00M | 1.17B | 995.00M | 686.00M | 781.00M | 778.00M | 827.00M | 798.00M |
| Interest Expense | 190.00M | 1.09B | 1.12B | 299.00M | 1.31B | 1.59B | 931.00M | 42.00M | 59.00M | 145.00M | 259.00M | 205.00M | 135.00M | 199.00M | 0.00 | 328.00M | 240.00M | 186.00M | 240.00M | 804.00M | 1.72B | 3.11B | 3.13B | 2.72B |
| Depreciation & Amortization | 17.19B | 18.48B | 19.50B | 20.47B | 18.80B | 16.24B | 22.03B | 23.78B | 36.56B | 36.71B | 33.17B | 32.93B | 33.55B | 32.12B | 0.00 | 14.35B | 10.01B | 9.79B | 10.57B | 11.36B | 14.77B | 17.82B | 18.50B | 19.38B |
| EBITDA | 113.04B | 87.14B | 79.86B | 74.71B | 70.83B | 84.47B | 84.53B | 67.06B | 80.33B | 72.88B | 84.94B | 78.16B | 79.86B | 74.61B | 0.00 | 60.10B | 53.49B | 33.77B | 34.85B | 40.71B | 33.54B | 33.48B | 33.40B | 43.51B |
| EBITDA Ratio | 25.56% | 21.87% | 22.90% | 22.94% | 21.12% | 28.06% | 22.30% | 18.87% | 20.76% | 20.35% | 24.64% | 25.15% | 34.51% | 28.44% | 0.00% | 14.45% | 11.34% | 10.50% | 12.66% | 15.05% | 9.34% | 13.98% | 13.41% | 11.48% |
| Operating Income | 86.44B | 68.66B | 61.17B | 52.56B | 45.80B | 75.03B | 57.73B | 31.64B | 43.77B | 36.17B | 51.77B | 52.91B | 85.08B | 45.41B | 0.00 | 39.39B | 30.16B | 25.54B | 33.51B | 26.84B | 18.78B | 20.36B | 17.71B | 21.66B |
| Operating Income Ratio | 19.55% | 17.24% | 17.36% | 16.51% | 14.98% | 21.65% | 16.34% | 9.22% | 12.01% | 10.85% | 15.20% | 15.88% | 24.75% | 10.98% | 0.00% | 10.05% | 8.51% | 7.22% | 9.33% | 7.69% | 5.23% | 5.38% | 4.72% | 5.78% |
| Total Other Income/Expenses | 10.81B | 2.76B | -1.06B | -299.00M | -1.31B | -1.59B | -1.88B | -1.35B | -2.37B | -8.93B | -2.00B | -7.88B | -38.89B | -3.11B | 0.00 | -14.45B | -575.00M | -2.01B | -663.00M | -3.60B | -3.40B | 904.00M | -7.90B | 215.00M |
| Income Before Tax | 97.25B | 67.57B | 60.05B | 52.26B | 44.49B | 73.44B | 55.85B | 30.29B | 41.40B | 27.25B | 49.77B | 45.03B | 46.18B | 42.30B | 0.00 | 38.82B | 23.53B | 24.87B | 29.90B | 15.38B | 16.99B | 12.46B | 21.87B | 22.58B |
| Income Before Tax Ratio | 21.99% | 16.96% | 17.05% | 16.42% | 14.55% | 21.19% | 15.80% | 8.83% | 11.36% | 8.17% | 14.61% | 13.51% | 13.44% | 10.22% | 0.00% | 9.90% | 6.64% | 7.04% | 8.33% | 4.41% | 4.73% | 3.29% | 5.82% | 6.02% |
| Income Tax Expense | 16.06B | 14.00B | 7.70B | 5.24B | 6.82B | 19.03B | 12.95B | 11.62B | 11.63B | 11.35B | 19.60B | 20.61B | 20.49B | 20.04B | 0.00 | 15.19B | 10.87B | 8.49B | 11.90B | 5.53B | 8.48B | 6.99B | 12.74B | 11.49B |
| Net Income | 81.19B | 53.57B | 52.35B | 47.03B | 67.08B | 54.41B | 42.90B | 18.67B | 29.77B | 15.90B | 30.08B | 24.20B | 25.61B | 22.20B | 0.00 | 23.48B | 12.69B | 16.27B | 17.93B | 10.02B | 8.49B | 5.54B | 9.40B | 11.27B |
| Net Income Ratio | 18.36% | 13.45% | 14.86% | 14.77% | 21.94% | 15.70% | 12.14% | 5.44% | 8.17% | 4.77% | 8.83% | 7.26% | 7.45% | 5.36% | 0.00% | 5.99% | 3.58% | 4.60% | 5.00% | 2.87% | 2.36% | 1.46% | 2.50% | 3.01% |
| EPS | 151.01 | 99.68 | 97.43 | 87.56 | 124.57 | 100.95 | 78.38 | 34.11 | 54.40 | 29.05 | 54.95 | 44.12 | 45.16 | 38.96 | 0.00 | 59.03 | 31.32 | 38.48 | 41.93 | 23.21 | 19.56 | 12.75 | 21.64 | 25.96 |
| EPS Diluted | 151.01 | 99.66 | 97.39 | 87.50 | 124.46 | 100.95 | 78.30 | 34.08 | 54.36 | 29.02 | 54.91 | 44.10 | 45.14 | 38.94 | 0.00 | 59.03 | 31.32 | 38.30 | 41.93 | 23.21 | 19.56 | 12.75 | 21.64 | 25.90 |
| Weighted Avg Shares Out | 537.63M | 537.43M | 537.27M | 537.11M | 538.54M | 539.01M | 547.29M | 547.29M | 547.29M | 547.35M | 547.39M | 548.45M | 567.03M | 569.71M | 570.94M | 397.72M | 405.27M | 422.92M | 427.64M | 431.50M | 433.75M | 434.24M | 434.24M | 434.24M |
| Weighted Avg Shares Out (Dil) | 537.63M | 537.57M | 537.51M | 537.48M | 539.01M | 539.01M | 547.86M | 547.86M | 547.72M | 547.83M | 547.77M | 548.73M | 567.30M | 570.03M | 570.94M | 397.72M | 405.27M | 424.88M | 427.64M | 431.50M | 433.75M | 434.24M | 434.24M | 435.29M |
Kyowa Kirin Announces Acceptance for Presentations at the European Academy of Dermatology and Venereology Congress 2023
Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating
Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.
Titian Software Supporting Kyowa Kirin's Central Sample Bank
Kyowa Kirin Designs New North American Headquarters to Accelerate Innovation, Collaboration, Culture
Kyowa Kirin To Cut Royalty Payment Rate To Ardelyx For Tenapanor In Cardiorenal Disorders
MEI Pharma, Kyowa Kirin Reveal Data From Zandelisib Trial In Follicular Lymphoma
Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients
AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
Kyowa Kirin: Agreement With Amgen Points To A Blockbuster Drug
Source: https://incomestatements.info
Category: Stock Reports